4728 related articles for article (PubMed ID: 29364287)
1. The biology and management of non-small cell lung cancer.
Herbst RS; Morgensztern D; Boshoff C
Nature; 2018 Jan; 553(7689):446-454. PubMed ID: 29364287
[TBL] [Abstract][Full Text] [Related]
2. Lung cancer biomarkers: present status and future developments.
Cagle PT; Allen TC; Olsen RJ
Arch Pathol Lab Med; 2013 Sep; 137(9):1191-8. PubMed ID: 23991729
[TBL] [Abstract][Full Text] [Related]
3. Targeted Therapy and Immunotherapy for Lung Cancer.
Naylor EC; Desani JK; Chung PK
Surg Oncol Clin N Am; 2016 Jul; 25(3):601-9. PubMed ID: 27261918
[TBL] [Abstract][Full Text] [Related]
4. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
5. The role of targeted therapy in non-small cell lung cancer.
Maione P; Rossi A; Airoma G; Ferrara C; Castaldo V; Gridelli C
Crit Rev Oncol Hematol; 2004 Jul; 51(1):29-44. PubMed ID: 15207252
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy.
Zheng H; Zeltsman M; Zauderer MG; Eguchi T; Vaghjiani RG; Adusumilli PS
Immunotherapy; 2017 Sep; 9(11):913-927. PubMed ID: 29338609
[TBL] [Abstract][Full Text] [Related]
7. The Use of EGFR Tyrosine Kinase Inhibitors in EGFR Wild-Type Non-Small-Cell Lung Cancer.
Stinchcombe TE
Curr Treat Options Oncol; 2016 Apr; 17(4):18. PubMed ID: 26961971
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers in Non-Small Cell Lung Cancer: Perspectives of Individualized Targeted Therapy.
Aoki MN; Amarante MK; de Oliveira CEC; Watanabe MAE
Anticancer Agents Med Chem; 2018; 18(15):2070-2077. PubMed ID: 30147015
[TBL] [Abstract][Full Text] [Related]
9. Role of immunotherapy in the treatment of advanced non-small-cell lung cancer.
Rijavec E; Genova C; Alama A; Barletta G; Sini C; Pronzato P; Coco S; Dal Bello MG; Savarino G; Truini A; Boccardo F; Grossi F
Future Oncol; 2014 Jan; 10(1):79-90. PubMed ID: 24328411
[TBL] [Abstract][Full Text] [Related]
10. Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.
Morgensztern D; Campo MJ; Dahlberg SE; Doebele RC; Garon E; Gerber DE; Goldberg SB; Hammerman PS; Heist RS; Hensing T; Horn L; Ramalingam SS; Rudin CM; Salgia R; Sequist LV; Shaw AT; Simon GR; Somaiah N; Spigel DR; Wrangle J; Johnson D; Herbst RS; Bunn P; Govindan R
J Thorac Oncol; 2015 Jan; 10(1 Suppl 1):S1-63. PubMed ID: 25535693
[TBL] [Abstract][Full Text] [Related]
11. Next-Generation Sequencing and Immunotherapy Biomarkers: A Medical Oncology Perspective.
Bernicker E
Arch Pathol Lab Med; 2016 Mar; 140(3):245-8. PubMed ID: 26927719
[TBL] [Abstract][Full Text] [Related]
12. Advances in molecular-based personalized non-small-cell lung cancer therapy: targeting epidermal growth factor receptor and mechanisms of resistance.
Jotte RM; Spigel DR
Cancer Med; 2015 Nov; 4(11):1621-32. PubMed ID: 26310719
[TBL] [Abstract][Full Text] [Related]
13. Lung Cancer: Management.
Mott TF
FP Essent; 2018 Jan; 464():27-30. PubMed ID: 29313655
[TBL] [Abstract][Full Text] [Related]
14. Personalized treatment of early-stage non-small-cell lung cancer: the challenging role of EGFR inhibitors.
Santarpia M; Altavilla G; Pitini V; Rosell R
Future Oncol; 2015; 11(8):1259-74. PubMed ID: 25832881
[TBL] [Abstract][Full Text] [Related]
15. Current WHO guidelines and the critical role of immunohistochemical markers in the subclassification of non-small cell lung carcinoma (NSCLC): Moving from targeted therapy to immunotherapy.
Osmani L; Askin F; Gabrielson E; Li QK
Semin Cancer Biol; 2018 Oct; 52(Pt 1):103-109. PubMed ID: 29183778
[TBL] [Abstract][Full Text] [Related]
16. Biomarkers for Immunotherapy.
Bustamante-Alvarez JG; Owen DH
Thorac Surg Clin; 2020 May; 30(2):207-214. PubMed ID: 32327179
[TBL] [Abstract][Full Text] [Related]
17. A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer.
Shi H; Guo J; Li C; Wang Z
Drug Des Devel Ther; 2015; 9():4989-96. PubMed ID: 26357465
[TBL] [Abstract][Full Text] [Related]
18. [Basis of Tumor Microenvironment Relevant to Immunotherapies for Brain Metastases of NSCLC].
Lan Q; Ji C; Yao Y
Zhongguo Fei Ai Za Zhi; 2019 Aug; 22(8):512-519. PubMed ID: 31451142
[TBL] [Abstract][Full Text] [Related]
19. Designing a definitive trial for adjuvant targeted therapy in genotype defined lung cancer: the ALCHEMIST trials.
Alden RS; Mandrekar SJ; Oxnard GR
Chin Clin Oncol; 2015 Sep; 4(3):37. PubMed ID: 26408304
[TBL] [Abstract][Full Text] [Related]
20. A Neuro-oncologist's Perspective on Management of Brain Metastases in Patients with EGFR Mutant Non-small Cell Lung Cancer.
McGranahan T; Nagpal S
Curr Treat Options Oncol; 2017 Apr; 18(4):22. PubMed ID: 28391420
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]